Literature DB >> 3162506

A possible zymogen self-destruct mechanism preventing pancreatic autodigestion.

H Rinderknecht1, N F Adham, I G Renner, C Carmack.   

Abstract

Incubation at 37 degrees C of human cationic trypsinogen purified by PAGE electrophoresis, results in development of proteolytic activity (enzyme Y) capable of rapidly degrading cationic and anionic trypsinogens to inert products. Enzyme Y appears to be a serine protease with a molecular weight of about 20,000 daltons and is different from any of the known pancreatic enzymes. The active enzyme may be derived from trypsinogen itself or a hitherto unrecognized precursor contaminating the trypsinogen fraction used in this work. Appearance of enzyme Y activity seems to be associated with the presence of traces of free trypsin. Enzyme Y possesses insignificant or no activity when tested with a variety of synthetic trypsin, chymotrypsin and other protease substrates. It is not inactivated by the specific trypsin and chymotrypsin inhibitors TLCK and TPCK, but its activity is reduced gradually by increasing concentrations of pancreatic secretory trypsin inhibitor. Ca2+ concentrations greater than 3 mM strongly inhibit enzyme Y, and diisopropylfluorophosphate completely inactivates it. The enzyme is stable when incubated at pH 1.9 and 37 degrees C for 30 min and its activity is not abolished by treatment with Hg2+. When added to pancreatic juice with low inhibitor content it causes rapid inactivation of zymogens without significant release of active enzymes or reduction of pancreatic trypsin inhibitor. Its physiological role may be perceived as a second line of defense against premature intrapancreatic activation of zymogens. Enzyme Y activity may be generated when trypsin inhibitor, the first line of defense, is sufficiently depleted by complex formation with inappropriately released trypsin to permit dissociation of a small amount of trypsin from this complex. This in turn may lead to activation of enzyme Y and inactivation of the zymogens of pancreatic proteases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162506     DOI: 10.1007/BF02788221

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  13 in total

Review 1.  Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation.

Authors:  H Rinderknecht
Journal:  Dig Dis Sci       Date:  1986-03       Impact factor: 3.199

2.  Lysosomal enzymes in pure pancreatic juice from normal healthy volunteers and chronic alcoholics.

Authors:  H Rinderknecht; I G Renner; H H Koyama
Journal:  Dig Dis Sci       Date:  1979-03       Impact factor: 3.199

3.  Trypsin inhibitor from human pancreas and pancreatic juice.

Authors:  M H Pubols; D C Bartelt; L J Greene
Journal:  J Biol Chem       Date:  1974-04-10       Impact factor: 5.157

4.  A sensitive assay for human enterokinase and some properties of the enzyme.

Authors:  H Rinderknecht; E R Engeling; M J Bunnell; M C Geokas
Journal:  Clin Chim Acta       Date:  1974-07-31       Impact factor: 3.786

5.  Pseudotrypsin. A modified bovine trypsin produced by limited autodigestion.

Authors:  R L Smith; E Shaw
Journal:  J Biol Chem       Date:  1969-09-10       Impact factor: 5.157

6.  A new, highly sensitive and specific assay for chymotrypsin.

Authors:  H Rinderknecht; R M Fleming
Journal:  Clin Chim Acta       Date:  1975-03-10       Impact factor: 3.786

7.  Characterization and purification of a kallikrein from human pancreatic juice and immunological comparison with other kallikreins.

Authors:  M Amouric; C Figarella
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1979-03

8.  Trypsinogen variants in pancreatic juice of healthy volunteers, chronic alcoholics, and patients with pancreatitis and cancer of the pancreas.

Authors:  H Rinderknecht; I G Renner; C Carmack
Journal:  Gut       Date:  1979-10       Impact factor: 23.059

9.  Fat necrosis - a cause of pancreatic parenchymal necrosis?

Authors:  H Schmidt; P G Lankisch
Journal:  Digestion       Date:  1978       Impact factor: 3.216

10.  Profiles of pure pancreatic secretions obtained by direct pancreatic duct cannulation in normal healthy human subjects.

Authors:  H Rinderknecht; I G Renner; A P Douglas; N F Adham
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

View more
  9 in total

Review 1.  New insights into hereditary pancreatitis.

Authors:  D C Whitcomb
Journal:  Curr Gastroenterol Rep       Date:  1999-04

Review 2.  Chymotrypsin C mutations in chronic pancreatitis.

Authors:  Jiayi Zhou; Miklós Sahin-Tóth
Journal:  J Gastroenterol Hepatol       Date:  2011-08       Impact factor: 4.029

Review 3.  Pathophysiology of chronic pancreatitis.

Authors:  Christina Brock; Lecia Møller Nielsen; Dina Lelic; Asbjørn Mohr Drewes
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

4.  Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y.

Authors:  Richárd Szmola; Miklós Sahin-Tóth
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

5.  Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis.

Authors:  Emmanuelle Masson; Jian-Min Chen; Virginie Scotet; Cédric Le Maréchal; Claude Férec
Journal:  Hum Genet       Date:  2008-01-03       Impact factor: 4.132

6.  Survival and morphology of isolated pancreatic acinar cells from rats with induced acute pancreatitis are not improved with anti-inflammatory drugs.

Authors:  F Richter; R Matthias
Journal:  Int J Pancreatol       Date:  1995-10

Review 7.  Development of the human pancreas and its exocrine function.

Authors:  Vijay Mehta; Puanani E Hopson; Yamen Smadi; Samit B Patel; Karoly Horvath; Devendra I Mehta
Journal:  Front Pediatr       Date:  2022-09-29       Impact factor: 3.569

Review 8.  Genetic aspects of tropical calcific pancreatitis.

Authors:  Heiko Witt; Eesh Bhatia
Journal:  Rev Endocr Metab Disord       Date:  2008-09       Impact factor: 9.306

9.  High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study.

Authors:  Shiren Sun; Lijie He; Ming Bai; Hongbao Liu; Yangping Li; Li Li; Yan Yu; Meilan Shou; Rui Jing; Liyuan Zhao; Chen Huang; Hanmin Wang
Journal:  Ann Saudi Med       Date:  2015 Sep-Oct       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.